Medicare GLP-1 Bridge Program Launches, 3.8 Million People Eligible
Taylor Wilson
Medicare began covering GLP-1 weight-loss drugs for the first time this week, charging eligible beneficiaries just $50 a month; but analysts say the actual pool is far smaller than headlines suggest, and the short-term revenue lift for Novo Nordisk and Eli Lilly is modest.
Which drugs are covered — and who qualifies?
The program covers Novo Nordisk's Wegovy (injection and tablet) and Eli Lilly's Zepbound KwikPen and Foundayo tablet, at a patient co-pay of $50 per month.
Eligibility requires Medicare Part D prescription coverage, a physician's prescription, prior authorization, and proof of qualifying BMI and medical conditions.
This means → it is not an open door for every overweight senior — each patient must clear a multi-step approval process.
13.3 million are obese on Medicare — why do only 3.8 million qualify?
A KFF analysis found 13.3 million Medicare beneficiaries met obesity or overweight criteria in 2023, but only about 3.8 million passed the Bridge program's specific eligibility filters.
The key exclusion: patients who can already access GLP-1 drugs through existing Part D benefits — those with type-2 diabetes, obstructive sleep apnea, or fatty liver disease — are not covered.
In plain terms = the program fills a gap only for people who had no reimbursement path before; everyone who already had one is excluded, which sharply narrows the pool.
How much revenue can the drugmakers expect — and why are analysts cautious?
Morningstar healthcare research director Karen Andersen noted both companies already struck a $245-per-dose deal with the Trump administration, and "the market has already priced in that low price."
She currently projects "no major revenue uplift from the Bridge program for U.S. GLP-1 therapy revenue."
BMO analyst Evan David Seigerman sees some incremental revenue for Novo Nordisk's Wegovy U.S. business this year, but says more upside "likely concentrates in 2027 and beyond"; he also flagged that operational rollout may slow actual patient enrollment.
What happens when the program expires in 2027 — and why is that the real question?
Bridge is an 18-month demonstration project set to end in December 2027; federal law explicitly bars Medicare from covering drugs for weight loss alone, so the program uses a demo waiver to sidestep that ban.
KFF's Juliette Cubanski said: "If there is no other pathway for Medicare coverage of GLP-1s for weight loss by the end of 2027, what happens then is really a big unknown."
This reflects a fundamental tension: GLP-1 drugs are widely seen as requiring long-term, even lifelong use — yet the policy paying for them has only an 18-month lifespan. The coverage-gap risk is the central variable for markets assessing the long-term Medicare-channel value of Novo Nordisk and Eli Lilly.
Content is for reference only, not financial advice.